Showing 1 - 6 results of 6 for search 'Balazs Hegedus', query time: 0.01s Refine Results
  1. 1
    Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer

    Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer by Eszter Molnár, Marcell Baranyi, Marcell Baranyi, Krisztina Szigeti, Luca Hegedűs, Fanni Bordás, Zsófia Gábriel, Gréta Petényi, József Tóvári, Balázs Hegedűs, Balázs Hegedűs, József Tímár

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma

    Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma by Sára Eszter Surguta, Marcell Baranyi, Laura Svajda, Mihály Cserepes, Ivan Ranđelović, Enikő Tátrai, Balázs Hegedűs, József Tóvári

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    BARD1 serum autoantibodies for the detection of lung cancer.

    BARD1 serum autoantibodies for the detection of lung cancer. by Maxim Pilyugin, Pascaline Descloux, Pierre-Alain André, Viktoria Laszlo, Balazs Dome, Balazs Hegedus, Sylvain Sardy, Samuel Janes, Andrea Bianco, Geoffrey J Laurent, Irmgard Irminger-Finger

    Published 2017-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Characterization of a novel sarcoma cell line with an EWSR1::POU2AF3 fusion

    Characterization of a novel sarcoma cell line with an EWSR1::POU2AF3 fusion by Hannah Schwab, Maximilian Kerkhoff, Maximilian Kerkhoff, Maximilian Kerkhoff, Pauline Plaumann, Pauline Plaumann, Pauline Plaumann, Stéphane Collaud, Uta Dirksen, Uta Dirksen, Uta Dirksen, Dirk Theegarten, Thomas Herold, Stavros Kalbourtzis, Servet Bölükbas, Balazs Hegedüs, Luca Hegedüs

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer

    Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer by Zhang Yang, Shun‐Qing Liang, Maria Saliakoura, Haitang Yang, Eric Vassella, Georgia Konstantinidou, Mario Tschan, Balazs Hegedüs, Liang Zhao, Yanyun Gao, Duo Xu, Haibin Deng, Thomas M Marti, Gregor J Kocher, Wenxiang Wang, Ralph A Schmid, Ren‐Wang Peng

    Published 2021-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study

    NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, si... by Albrecht Stenzinger, Farastuk Bozorgmehr, Michael Thomas, Hauke Winter, Michael Allgäeuer, Alexander Schramm, Servet Bolukbas, Marietta Kirchner, Martin Schuler, Petros Christopoulos, Marc Schneider, Romina M Roesch, Johannes Schnorbach, Laura V Klotz, Raffaella Griffo, Marcel Wiesweg, Fabian Doerr, Balazs Hegedüs, Jelena Cvetkovic, Martin E Eichhorn, Florian Eichhorn

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: